国家医保局详解创新药新政：全链条支持创新药发展

Core Insights - The article discusses the recent measures introduced by the National Healthcare Security Administration (NHSA) and the National Health Commission (NHC) to support the development of innovative drugs in China, focusing on policy support and pricing guarantees for companies while ensuring accessibility and safety for the public [1][2]. Group 1: Policy Measures - The "Several Measures to Support the High-Quality Development of Innovative Drugs" includes 16 measures across five areas, addressing the entire chain of innovative drug development, approval, hospital use, and multi-channel payment [1]. - The NHSA has made significant progress in the approval of innovative drugs, with the number of Class 1 innovative drugs approved reaching 48 in 2024, over five times the number in 2018, and nearly 40 already in the first half of this year [1]. Group 2: Multi-Payment System - The NHSA is establishing a multi-payment system for innovative drugs, which includes regular adjustments to the medical insurance drug list and the introduction of a commercial health insurance innovative drug list [2][3]. - The commercial health insurance innovative drug list will focus on highly innovative drugs with significant clinical value that exceed the basic medical insurance coverage, enhancing the multi-layered medical security system [2]. Group 3: Market Dynamics - The commercial health insurance market in China has been growing rapidly, with the original insurance premium income for commercial health insurance reaching 977.3 billion yuan in 2024, a year-on-year increase of 8.2% [3]. - The NHSA aims to streamline the application process for innovative drugs to be included in both the medical insurance and commercial health insurance lists, reducing the administrative burden on companies [3][4]. Group 4: Support for Global Expansion - The measures also aim to support the global market development of Chinese innovative drugs, with over 90 overseas licensing transactions completed by Chinese pharmaceutical companies in 2024, totaling over 50 billion USD [6]. - The NHSA will facilitate the entry of domestic drugs into ASEAN countries and support innovative drugs in overseas markets, including the implementation of price confidentiality for certain drugs [6][7].